CHICAGO — A cohort of patients with diabetic macular edema receiving abicipar pegol every 8 weeks showed “comparable” gains in visual acuity when compared with every 4-week dosing with ranibizumab, according to a presenter here. Tarek S. Hassan, MD, reported results of the PALM study at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting. In the multicenter, double masked, phase 2 trial supported by Allergan, 43 patients received 1 mg abicipar every 8 weeks, 41 patients received 2 mg abicipar every 8 weeks, 45 patients received 2 mg (Read more...)
Uncategorized